Courier service EMS
Other transport services
Air India Post International
Payment in the bank on the invoice
Bevacizumab is a generic form of brand name Abevmy 400mg necessary for the anti-cancer medication, which belongs to a group of drugs knowns as monoclonal antibodies. An antibody is a molecule produced by the body in response to a foreign antigen. A monoclonal antibody is made in the laboratory to target and prevents certain proteins. These agents are very essential for the molecules which they are formed against and are therefore called targeted therapies.
Abevmy 400mg is indicated for the treatment of following conditions;
Bevacizumab consist on targets a cancer cell protein called vascular endothelial growth factor (VEGF). This protein helps cancers to develop blood vessels, so they can have food and oxygen from the blood. All cancers require a blood supply to be able to survive and develop.
Bevacizumab stops this protein and inhibits the cancer from growing blood vessels, so it is macerated and can't grow. Treatments that prohibits the development of a blood supply are called anti-angiogenesis treatments.
The pharmacokinetic form of Abevmy 400mg is assayed by measuring total serum Bevacizumab concentration.
The volume of distribution is 2.9 (22%) L
The terminal half-life period of Bevacizumab is 20days (11 to 50days)
Key point: Abevmy do not administered before at least 28 days following surgery and the wound is completely cured
The usual dosage of Abevmy is 15mg/kg IV for every 3 weeks by co administration with carboplatin and paclitaxel
The usual dosage of Abevmy by combination with 5-fluorouracil based chemotherapy
The usual dose is 10mg/kg of Abevmy administered IV for every 2 weeks
The usual dosage of Abevmy; 10mg/kg of Abevmy for every 2 weeks by combination with paclitaxel, pegylated liposomal doxorubicin or topotecan
The usual dosage of Abevmy; 15mg/kg of Abevmy given through IV for every 3 weeks by combining with topotecan
The recommended dosage of Abevmy; 15mg/kg given IV for 3 weeks in concomitant with carboplatin and paclitaxel for 6 to 8 cycles
The recommended dosage of Abevmy; 15mg/kg of Abevmy given IV for 3 weeks by combining with gemcitabine & carboplatin for 6 to 10 cycles
The recommended dosage of Abevmy is 10mg/kg IV for every 2 weeks by concomitant use with interferon alfa
The usual dosage of Abevmy; 15mg/kg of Abevmy 400mg given intravenously for every 3 weeks by concomitant with paclitaxel and cisplatin or with paclitaxel and topotecan
Abevmy used as intravenous solution
At initial infusion: given IV infusion over 90 minutes
Following infusions: give second infusion over 60 minutes, if tolerated
Administer all following infusion over 30minutes
Abevmy IV infusion is prepared in aseptic condition
Abevmy 400mg containing 16ml solution whereas 100mg containing 4ml
Abevmy dilute into 100ml of 0.9% NS
Do not dilute with dextrose solution
Discard the remaining portion which is left in a vial
While concomitant use of Abevmy 400mg with paclitaxel & carboplatin, causes reduces in exposure of paclitaxel after four cycles of therapy
While getting patients with paclitaxel & carboplatin leads to raises the paclitaxel exposure at day 6
No contraindication occurred
Surgery and wound healing complications observes while Administration may result in the development of fatal wound dehiscence. Discontinue treatment in patients with wound dehiscence requiring medical intervention.
Serious or lethal hemorrhage, haemoptysis, gastrointestinal bleeding, hematemesis, CNS hemorrhage, and vaginal bleeding are increased in bevacizumab-treated patients. Do not administer the drug along with severe hemorrhage.
Severe, sometimes lethal, arterial thromboembolic events (ATE) involving cerebral infarction, transient ischemic attacks, myocardial infarction, angina, and a variety of other ATE; discontinue bevacizumab for severe ATE
Due Abevmy 400mg may have high relative risk for heart failure has been along with therapy
Advise females of reproductive possible to use active contraception during treatment with and for 6 months after the final dose
Pregnancy category: D
Abevmy 400mg may cause fetal harm to infants based on findings from animal studies and mechanism of action. The drug produces malformation while using during pregnancy.
Excretion into human breast milk is unknown. Breast feeding is also not recommended
Abevmy 400mg vial should be stored at 2 to 8oC (36 to 46oF)
Single use vial and protect from light
Do not freeze or shake the vial
If patient missed to have the dose or forget the cycle means must consult with oncologist and follow the regular dosing schedule
Do not take overdose. Consult the doctor immediately
Вижте офертите за акции. Хубаво е да се спаси!View all